We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TNFi

News List

Scipher Medicine Increases Patient Access for PrismRA® by Expanding Intended Use in Autoimmune Patients b3cnewswire
July 30, 2021
Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced the expanded clinical utility and intended use to include most rheumatoid arthritis (RA) patients for its commercially available PrismRA.
Scipher Medicine Announces PrismRA® Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class b3cnewswire
June 25, 2021
Scipher Medicine today announced positive results from a multicenter, blinded prospective observational clinical study assessing the ability of the PrismRA test to predict which patients with rheumatoid arthritis
Tremfya® improves psoriatic arthritis joint function and skin clearance europeanpharmaceuticalreview
June 08, 2021
Over 50 percent of psoriatic arthritis patients treated with Tremfya® (guselkumab) achieved ≥20 percent improvement in joint symptoms and complete skin clearance at one year.